人工智能在抗肥胖药物的发现:解锁下一代治疗方法
Amit Gangwal1, Antonio Lavecchia2
1Department of Natural Product Chemistry, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001 Maharashtra, India.
Drug discovery today
|March 19, 2025
概括
人工智能 (AI) 加快了新型抗肥胖药物的发现,特别是类似葡萄糖-1受体激活剂 (GLP-1RA). 人工智能为克服当前肥胖治疗的局限性和开发下一代治疗方法提供了一个有希望的途径.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 肥胖是一种具有重大健康风险的复杂疾病,需要超越传统方法的先进治疗策略.
- 目前的抗肥胖药物在有效性,耐受性和长期有效性方面存在局限性,这推动了对新药开发的需求.
- 人工智能 (AI) 为制药研发提供了一种变革性的方法.
研究的目的:
- 审查人工智能在发现下一代抗肥胖疗法的应用.
- 要突出AI在识别新型抗肥胖的作用,特别关注类似葡萄糖-1受体激动剂 (GLP-1RA).
- 讨论AI整合在抗肥胖药物发现中的挑战和未来方向.
主要方法:
- 在药物发现中对AI应用的文献综述.
- 分析AI对识别和优化抗肥胖药物候选者的影响.
- 探索AI在开发基于的治疗方法中的作用,包括GLP-1RA.
主要成果:
- 人工智能显著加快了对肥胖治疗的潜在候选药物的识别.
- 人工智能有助于优化治疗策略和发现新的抗肥胖.
- 人工智能驱动的方法在解决现有抗肥胖药物的局限性方面表现有前途.
结论:
- 人工智能是推动开发创新型抗肥胖治疗的关键工具.
- 人工智能的整合,特别是在GLP-1RA的背景下,为下一代肥胖疗法提供了一个有希望的途径.
- 克服整合挑战对于充分发挥AI在重塑抗肥胖药物发现方面的潜力至关重要.
相关概念视频
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Structure-Activity Relationships and Drug Design
471
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
471
Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
Obesity
356
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
356
Regulation of Food Intake
166
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
166
Principles of Drug Action
5.7K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.7K


